New Gene Inhibitor Drug for Patients with MTAP-Deleted Tumors
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.
Researchers are testing a drug combination for melanoma in pancreatic cancer patients with a BRAF genetic mutation.
Researchers are testing a PARP inhibitor that is effective for cancers in pancreatic cancer patients with DNA repair mutations.
A clinical trial for at-risk people is looking for biomarkers that can indicate pancreatic cancer is growing.
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
A clinical trial for pancreatic cancer patients with a BRCA mutation uses a combination of chemotherapy, vitamins, and stem cells.
An investigational drug is being used in an expanded access trial for advanced pancreatic and other cancer patients with specific genetic changes.
Researchers are using blood samples to follow people considered at-risk for developing pancreatic cancer in a trial looking for early detection biomarkers.
Relatives of pancreatic cancer patients or people who carry certain mutations can participate in an early detection clinical trial.
Researchers are trying kinase inhibitors that are effective for breast cancer, colorectal cancer, and melanoma on pancreatic cancer.